You are here: Industry Insights > Takeda

News List

Evotec, Takeda Enter Multi-RNA Target Alliance contractpharma
March 23, 2021
Evotec SE has entered into a multi-RNA target alliance with Takeda Pharmaceutical Co. to discover and develop small molecule therapeutics for highly attractive targets that are difficult to address via more conventional approaches.
Anima signs new strategic collaboration deal with Takeda pharmaceutical-business-review
March 22, 2021
Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.
Takeda submits New Drug Application for lanadelumab in Japan pharmaceutical-business-review
March 18, 2021
Japan-based, R&D-driven Takeda Pharmaceutical Company Limited has submitted a New Drug Application (NDA) for lanadelumab to the Ministry of Health, Labour and Welfare (MHLW) in Japan.
Takeda and IDT Support Manufacturing of J&J’s COVID-19 Vaccine contractpharma
March 16, 2021
Takeda Pharmaceutical has entered a mutual agreement with IDT Biologika GmbH, a contract development and manufacturing organization (CDMO), to utilize capacity at IDT previously reserved for Takeda’s dengue vaccine candidate (TAK-003) to manufacture ...
Takeda exercises option to acquire Maverick Therapeutics for $525m pharmaceutical-technology
March 11, 2021
Takeda Pharmaceutical Company has exercised its option to acquire Maverick Therapeutics for a pre-negotiated upfront payment and potential development and regulatory milestones totalling up to $525m.
Takeda secures global rights to develop and commercialise soticlestat pharmaceutical-business-review
March 09, 2021
Takeda Pharmaceutical Company has entered into an exclusive agreement to secure global rights from Ovid Therapeutics to develop and commercialise the investigational medicine soticlestat (TAK-935/OV935) for the treatment of developmental and epileptic ...
Takeda to sell diabetes products portfolio to Teijin Pharma for $1.25bn pharmaceutical-technology
March 02, 2021
Takeda Pharmaceutical Company has signed an agreement to sell four non-core type 2 diabetes products in Japan to Teijin Pharma for JPY133bn ($1.25bn).
Takeda President Becomes PhRMA Board Chair-Elect americanpharmaceuticalreview
February 09, 2021
The Pharmaceutical Research and Manufacturers of America (PhRMA) elected two new officers to its board of directors. Ramona Sequeira, president of Takeda Pharmaceuticals USA, Inc. was named chair-elect. Sequeira formerly held the position of board ...
Takeda concludes sale of select OTC and non-core assets to Hypera Pharma expresspharma
February 01, 2021
Takeda Pharmaceutical Company announced the completion of its previously-announced sale of a portfolio of select products sold in Latin America to Hypera S.A. for a total value of $825 million. This divestment agreement was first announced in March 2020.
Evozyne, Takeda Ink Strategic Protein Design Agreement contractpharma
January 29, 2021
Takeda will use Evozyne's evolution-based protein design technology to research and develop proteins for next-gen gene therapies.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page